NO20004413D0 - HIV peptider, antigener, vaksine, blandinger, immunoassay, kit og en fremgangmÕte for pÕvisning av antistoffer som blir infusert av HIV - Google Patents

HIV peptider, antigener, vaksine, blandinger, immunoassay, kit og en fremgangmÕte for pÕvisning av antistoffer som blir infusert av HIV

Info

Publication number
NO20004413D0
NO20004413D0 NO20004413A NO20004413A NO20004413D0 NO 20004413 D0 NO20004413 D0 NO 20004413D0 NO 20004413 A NO20004413 A NO 20004413A NO 20004413 A NO20004413 A NO 20004413A NO 20004413 D0 NO20004413 D0 NO 20004413D0
Authority
NO
Norway
Prior art keywords
hiv
infused
immunoassay
vaccine
antigens
Prior art date
Application number
NO20004413A
Other languages
English (en)
Other versions
NO20004413L (no
NO314588B1 (no
Inventor
Birger Soerensen
Original Assignee
Bionor As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor As filed Critical Bionor As
Priority to NO20004413A priority Critical patent/NO314588B1/no
Publication of NO20004413D0 publication Critical patent/NO20004413D0/no
Priority to NZ535148A priority patent/NZ535148A/en
Priority to EP01961444A priority patent/EP1322665B1/en
Priority to AU8270601A priority patent/AU8270601A/xx
Priority to HU0303134A priority patent/HUP0303134A3/hu
Priority to CNB018157424A priority patent/CN1282656C/zh
Priority to BR0114036-1A priority patent/BR0114036A/pt
Priority to AT01961444T priority patent/ATE406380T1/de
Priority to EP07014954A priority patent/EP1878742A3/en
Priority to PCT/NO2001/000362 priority patent/WO2002020554A2/en
Priority to NZ524556A priority patent/NZ524556A/en
Priority to DE60135564T priority patent/DE60135564D1/de
Priority to EA200300336A priority patent/EA006308B1/ru
Priority to CA002421193A priority patent/CA2421193A1/en
Priority to CNA2006101517487A priority patent/CN101104636A/zh
Priority to ES01961444T priority patent/ES2312465T3/es
Priority to SK402-2003A priority patent/SK287917B6/sk
Priority to AU2001282706A priority patent/AU2001282706B2/en
Priority to US10/129,331 priority patent/US7009037B2/en
Priority to JP2002525174A priority patent/JP2004508381A/ja
Priority to ZA200301740A priority patent/ZA200301740B/en
Priority to ARP010104196A priority patent/AR033998A1/es
Priority to MYPI20014139A priority patent/MY136081A/en
Publication of NO20004413L publication Critical patent/NO20004413L/no
Publication of NO314588B1 publication Critical patent/NO314588B1/no
Priority to HK04102846A priority patent/HK1059940A1/xx
Priority to US11/211,576 priority patent/US7612168B2/en
Priority to AU2007202739A priority patent/AU2007202739B2/en
Priority to ARP080105262A priority patent/AR071262A2/es
Priority to JP2011128389A priority patent/JP2011219481A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20004413A 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV NO314588B1 (no)

Priority Applications (28)

Application Number Priority Date Filing Date Title
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
ZA200301740A ZA200301740B (en) 2000-09-04 2001-09-03 HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines.
CNA2006101517487A CN101104636A (zh) 2000-09-04 2001-09-03 来自gag p17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
SK402-2003A SK287917B6 (sk) 2000-09-04 2001-09-03 Peptide derived from HIV-1gag p17, antigen comprising the peptide and use thereof, vaccine composition, antibody, nucleic acid, expression vector and host cell
ES01961444T ES2312465T3 (es) 2000-09-04 2001-09-03 Peptidos de vih de regiones conservadas en gag p17 y sus aplicaciones, tales como vacunas.
HU0303134A HUP0303134A3 (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
EP01961444A EP1322665B1 (en) 2000-09-04 2001-09-03 Hiv peptides from conserved regions in gag p17 and their applications, such as vaccines
BR0114036-1A BR0114036A (pt) 2000-09-04 2001-09-03 Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv
AT01961444T ATE406380T1 (de) 2000-09-04 2001-09-03 Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen
EP07014954A EP1878742A3 (en) 2000-09-04 2001-09-03 HIV peptides, antigens, vaccine compositions, immunoassay and a method of detecting antibodies induced by HIV
PCT/NO2001/000362 WO2002020554A2 (en) 2000-09-04 2001-09-03 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
NZ524556A NZ524556A (en) 2000-09-04 2001-09-03 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
DE60135564T DE60135564D1 (de) 2000-09-04 2001-09-03 Hiv-peptide aus konservierten regionen in gag p17 und deren anwendung z.b. in impfstoffen
AU2001282706A AU2001282706B2 (en) 2000-09-04 2001-09-03 HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines
CA002421193A CA2421193A1 (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions,immunoassay kit and a method of detecting antibodies induced by hiv
NZ535148A NZ535148A (en) 2000-09-04 2001-09-03 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
AU8270601A AU8270601A (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
CNB018157424A CN1282656C (zh) 2000-09-04 2001-09-03 来自gagp17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
EA200300336A EA006308B1 (ru) 2000-09-04 2001-09-03 Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
US10/129,331 US7009037B2 (en) 2000-09-04 2001-09-03 Modified HIV-1gag p17 peptide and immunogenic composition
JP2002525174A JP2004508381A (ja) 2000-09-04 2001-09-03 Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法
MYPI20014139A MY136081A (en) 2000-09-04 2001-09-04 Modified hiv - 1gag p17 peptide and immunogenic composition
ARP010104196A AR033998A1 (es) 2000-09-04 2001-09-04 Peptidos de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih
HK04102846A HK1059940A1 (en) 2000-09-04 2004-04-22 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
US11/211,576 US7612168B2 (en) 2000-09-04 2005-08-26 Modified HIV peptides, antigens, compositions, immunoassay kit and a method of detecting antibodies induced by HIV
AU2007202739A AU2007202739B2 (en) 2000-09-04 2007-06-13 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ARP080105262A AR071262A2 (es) 2000-09-04 2008-12-03 Peptidos derivados de una proteina de vih-1gagp24, composiciones de vacunas kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih
JP2011128389A JP2011219481A (ja) 2000-09-04 2011-06-08 Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV

Publications (3)

Publication Number Publication Date
NO20004413D0 true NO20004413D0 (no) 2000-09-04
NO20004413L NO20004413L (no) 2002-03-05
NO314588B1 NO314588B1 (no) 2003-04-14

Family

ID=19911533

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004413A NO314588B1 (no) 2000-09-04 2000-09-04 HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV

Country Status (20)

Country Link
US (2) US7009037B2 (no)
EP (2) EP1322665B1 (no)
JP (2) JP2004508381A (no)
CN (2) CN101104636A (no)
AR (2) AR033998A1 (no)
AT (1) ATE406380T1 (no)
AU (3) AU8270601A (no)
BR (1) BR0114036A (no)
CA (1) CA2421193A1 (no)
DE (1) DE60135564D1 (no)
EA (1) EA006308B1 (no)
ES (1) ES2312465T3 (no)
HK (1) HK1059940A1 (no)
HU (1) HUP0303134A3 (no)
MY (1) MY136081A (no)
NO (1) NO314588B1 (no)
NZ (2) NZ524556A (no)
SK (1) SK287917B6 (no)
WO (1) WO2002020554A2 (no)
ZA (1) ZA200301740B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398816A1 (en) 2000-02-04 2001-08-09 Duke University Human immunodeficiency virus vaccine
ATE425204T1 (de) * 2005-08-26 2009-03-15 Novo Nordisk As Verfahren zur modifizierung eines makromolekularen systems
FI120376B (fi) * 2007-01-17 2009-09-30 Next Biomed Technologies Nbt O Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi) 2007-03-07 2009-09-30 Next Biomed Technologies Nbt O Menetelmä fuusiopolypeptidin valmistamiseksi
EP2344143A1 (en) 2008-09-09 2011-07-20 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
US9733242B2 (en) 2012-10-07 2017-08-15 Sevident, Inc. Devices for capturing analyte
FR2957933B1 (fr) * 2010-03-24 2012-04-27 Seppic Sa Vaccin vivant pour maladies aviaires
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012204955B2 (en) * 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
IN2014KN02769A (no) * 2012-06-06 2015-05-08 Bionor Immuno As
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
CN105102427B (zh) 2013-03-21 2018-09-07 赛诺菲-安万特德国有限公司 含有环状酰亚胺的肽产物的合成
EP2976331B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of hydantoin containing peptide products
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
CN116064678A (zh) 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
EP3413926A4 (en) 2016-02-08 2019-10-09 American Gene Technologies International, Inc. HIV VACCINATION AND IMMUNOTHERAPY
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP3607072A4 (en) 2017-04-03 2021-01-06 American Gene Technologies International Inc. COMPOSITIONS AND METHODS OF TREATMENT OF PHENYLCETONURISM
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
RU2727673C1 (ru) * 2019-08-09 2020-07-22 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Антитела против белка р17 ВИЧ-1 субтипа А
GB2610556A (en) * 2021-09-02 2023-03-15 113 Botanicals Ltd Extraction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
DE4039925A1 (de) 1990-12-14 1992-06-17 Behringwerke Ag Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung
SE9101863D0 (sv) * 1991-06-13 1991-06-13 Replico Medical Ab Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
WO1998029551A1 (en) 1997-01-02 1998-07-09 Universidade Federal De Minas Gerais THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN HYBRID PROTEIN (p24/p17) DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUSES (HIV-1)
GB9703802D0 (en) * 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
WO1999058658A2 (en) * 1998-05-13 1999-11-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV

Also Published As

Publication number Publication date
ATE406380T1 (de) 2008-09-15
NZ524556A (en) 2005-01-28
JP2004508381A (ja) 2004-03-18
NO20004413L (no) 2002-03-05
SK4022003A3 (en) 2003-09-11
EP1878742A3 (en) 2008-04-30
JP2011219481A (ja) 2011-11-04
CN1460111A (zh) 2003-12-03
CN1282656C (zh) 2006-11-01
ES2312465T3 (es) 2009-03-01
MY136081A (en) 2008-08-29
EP1878742A2 (en) 2008-01-16
SK287917B6 (sk) 2012-03-02
WO2002020554A3 (en) 2002-06-13
AU8270601A (en) 2002-03-22
AU2001282706B2 (en) 2007-03-22
EA200300336A1 (ru) 2003-08-28
AR071262A2 (es) 2010-06-09
AU2007202739A1 (en) 2007-07-05
BR0114036A (pt) 2003-07-22
WO2002020554A2 (en) 2002-03-14
EA006308B1 (ru) 2005-10-27
HUP0303134A3 (en) 2012-09-28
CA2421193A1 (en) 2002-03-14
DE60135564D1 (de) 2008-10-09
NO314588B1 (no) 2003-04-14
US20070237783A1 (en) 2007-10-11
NZ535148A (en) 2007-06-29
HK1059940A1 (en) 2004-07-23
EP1322665A2 (en) 2003-07-02
AR033998A1 (es) 2004-01-21
HUP0303134A2 (hu) 2005-03-29
CN101104636A (zh) 2008-01-16
AU2007202739B2 (en) 2009-12-03
US20040115615A1 (en) 2004-06-17
ZA200301740B (en) 2004-06-21
US7612168B2 (en) 2009-11-03
US7009037B2 (en) 2006-03-07
EP1322665B1 (en) 2008-08-27

Similar Documents

Publication Publication Date Title
NO20004413D0 (no) HIV peptider, antigener, vaksine, blandinger, immunoassay, kit og en fremgangmÕte for pÕvisning av antistoffer som blir infusert av HIV
CY1106820T1 (el) Ανοσοδοκιμασιες για αντι-hcv αντισωματα
NO20032549L (no) Humaniserte antistoffer som gjenkjenner beta-amyloid-peptid
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
WO2003011899A3 (en) Antigenic polypeptides
NO20004412D0 (no) HIV regulatoriske og hjelpepeptider, antigener, vaksine, blandinger, immunoassay, kit og en fremgangsmÕte for pÕvisning av antistoffer som blir infusert av HIV
NO20026121D0 (no) Streptokokkantigener
HK1096975A1 (en) Monoclonal antibody against influenza b virus and immunoassay instrument using the antibody
NO20051715L (no) HCV assay
DK1504266T3 (da) Fremgangsmåde til samtidig detektering af en infekteret mikroorganismes antigen og antistof
EP1412538A4 (en) PROCESS FOR SIMULTANEOUS DETECTION OF HCV ANTIGENES AND HCV ANTIBODIES
AU2002217213A1 (en) Human monoclonal antibody directed against the influenza virus or a fragment thereof
DK1164375T3 (da) Assay til antitransglutaminaseantistoffer
ZA200202477B (en) A hepatitis C antigen-antibody combination assay for the early detection of infection.
AU2002220924A1 (en) Antibodies, peptides, analogs and uses thereof
EP1342727A4 (en) ANTIBODIES TO NORWALK VIRUS AND METHOD FOR DETECTING VIRUSES USING THE ANTIBODY
AU2002219290A1 (en) Proteinic antigens inducing antibodies neutralising hiv virus
DK1366080T3 (da) Naturlige antistoffer med virkning mod HIV-virus
AU2003240866A1 (en) Antibodies, peptides and vaccines against hiv-1 virus
DK1503799T3 (da) Immunogent, monoklonalt antistof
HUP0302103A3 (en) Detection of infectious agents using antigen mimics
EP1829891A3 (en) Immunoassays for Anti-HCV Antibodies
AU2002355912A1 (en) Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope
AU2002347250A1 (en) Polypeptide antigen forming a mimetic structure of the gp41 intermediate state
NO996412D0 (no) Antigene peptider

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees